Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options

ISSN: 1875-6417 (Online)
ISSN: 1573-3998 (Print)

Volume 11, 4 Issues, 2015

Download PDF Flyer

Current Diabetes Reviews

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Norman E. Cameron
University of Aberdeen
Aberdeen, Scotland

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options

Current Diabetes Reviews, 9(6): 491-498.

Author(s): Nicola Pescosolido, Federica Pranno and Giuseppe Buomprisco.

Affiliation: University “Sapienza” of Rome, Faculty of Medicine and Dentistry, Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Viale del Policlinico 155, 00161, Rome, Italy.


The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.


Anti-VEGF, diabetic macular edema, diabetes, neovascularization, rethinopathy, vision loss prevention.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 6
First Page: 491
Last Page: 498
Page Count: 8
DOI: 10.2174/15733998113096660083

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science